Blood Res 2017; 52(4):
Published online December 31, 2017
https://doi.org/10.5045/br.2017.52.4.285
© The Korean Society of Hematology
1Department of Hematology and Oncology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea.
2Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
3Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Correspondence to : Cheolwon Suh, M.D., Ph.D. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. csuh@amc.seoul.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Age and performance status are important prognostic factors in primary central nervous system (CNS) lymphoma. Although several prognostic models have been proposed, there is no consensus on the optimal model for patients with diffuse large B-cell histology.
Seventy-seven patients with primary CNS diffuse large B-cell lymphoma were retrospectively analyzed to determine factors affecting survival. Three Western models were applied to our eligible patients; we devised a novel model based on our findings.
The median patient age was 59 years (range, 29?77); the median event-free and overall survival (OS) durations were 35.9 and 12.6 months, respectively. Nottingham/Barcelona and Memorial Sloan Kettering Cancer Center models were applicable to our cohorts. Multivariate analysis showed that advanced age, multifocal lesions, and high cerebrospinal fluid (CSF) protein concentrations were correlated significantly. A novel model for predicting prognosis was then developed based on these variables. Each variable was assigned 1 point; patients with a total score of 0, 1, 2, and 3 were categorized into the low- (N=17), moderate- (N=26), high- (N=14), and very high-risk groups (N=4), respectively. Sixty-one patients were eligible considering our model; the median OS was 58.2, 34.8, 9.0, and 1.8 months in the low-, moderate-, high-, and very high-risk groups, respectively (
Advanced age, multifocal lesions, and high CSF protein concentration were adversely related with prognosis. Our model can be helpful in pre-treatment risk stratification for patients with primary CNS lymphoma with diffuse large B-cell histology.
Keywords Central nervous system, Lymphoma, Prognosis, Survival
Blood Res 2017; 52(4): 285-292
Published online December 31, 2017 https://doi.org/10.5045/br.2017.52.4.285
Copyright © The Korean Society of Hematology.
Yongchel Ahn1, Heui June Ahn1, Dok Hyun Yoon2, Jung Yong Hong2, Changhoon Yoo2, Shin Kim2, Jooryung Huh3, and Cheolwon Suh2*
1Department of Hematology and Oncology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea.
2Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
3Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Correspondence to:Cheolwon Suh, M.D., Ph.D. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. csuh@amc.seoul.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Age and performance status are important prognostic factors in primary central nervous system (CNS) lymphoma. Although several prognostic models have been proposed, there is no consensus on the optimal model for patients with diffuse large B-cell histology.
Seventy-seven patients with primary CNS diffuse large B-cell lymphoma were retrospectively analyzed to determine factors affecting survival. Three Western models were applied to our eligible patients; we devised a novel model based on our findings.
The median patient age was 59 years (range, 29?77); the median event-free and overall survival (OS) durations were 35.9 and 12.6 months, respectively. Nottingham/Barcelona and Memorial Sloan Kettering Cancer Center models were applicable to our cohorts. Multivariate analysis showed that advanced age, multifocal lesions, and high cerebrospinal fluid (CSF) protein concentrations were correlated significantly. A novel model for predicting prognosis was then developed based on these variables. Each variable was assigned 1 point; patients with a total score of 0, 1, 2, and 3 were categorized into the low- (N=17), moderate- (N=26), high- (N=14), and very high-risk groups (N=4), respectively. Sixty-one patients were eligible considering our model; the median OS was 58.2, 34.8, 9.0, and 1.8 months in the low-, moderate-, high-, and very high-risk groups, respectively (
Advanced age, multifocal lesions, and high CSF protein concentration were adversely related with prognosis. Our model can be helpful in pre-treatment risk stratification for patients with primary CNS lymphoma with diffuse large B-cell histology.
Keywords: Central nervous system, Lymphoma, Prognosis, Survival
International Extranodal Lymphoma Study Group (IELSG) model in our cohort.
Nottingham/Barcelona model in our cohort.
Memorial Sloan-Kettering Cancer Center (MSKCC) model in our cohort.
Newly proposed Asan Medical Center (AMC) prognostic model.
Abbreviations: ASCT, autologous stem cell transplantation; CR, complete response; CSF, cerebrospinal fluid; ECOG, Eastern Cooperative Oncology Group; IELSG, International Extranodal Lymphoma Study Group; KPS, Karnofsky Performance Status; LDH, lactate dehydrogenase; MSKCC, Memorial Sloan-Kettering Cancer Center; NE, not evaluable; PD, progressive disease; PR, partial response; RT, radiotherapy; SD, stable disease; WBRT, whole brain radiotherapy..
Abbreviations: ASCT, autologous stem cell transplantation; CR, complete response; CTx, chemotherapy; NE, not evaluable; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease; WBRT, whole brain radiotherapy..
Abbreviations: ASCT, autologous stem cell transplantation; β2-MG, β2-microglobulin; CR, complete response; CSF, cerebrospinal fluid; ECOG PS, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase; N/A, not applicable; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease..
Abbreviations: CI, confidence interval; CSF, cerebrospinal fluid; ECOG PS, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase..
Abbreviations: AMC, Asan Medical Center; CSF, cerebrospinal fluid; ECOG PS, Eastern Cooperative Oncology Group Performance Status; IELSG, International Extranodal Lymphoma Study Group; LDH, lactate dehydrogenase; MSKCC, Memorial Sloan-Kettering Cancer Center..
Dong Won Baek, Hee Jeong Cho, Jae Heung Bae, Sang Kyun Sohn, Joon Ho Moon
Blood Res 2020; 55(2): 99-106Dong Won Baek, Jung Min Lee, Juhyung Kim, Hee Jeong Cho, Sang Kyun Sohn, Ji Yeon Ham, Soon Hee Chang, Joon Ho Moon, Deok-Hwan Yang
Blood Res 2021; 56(2): 65-71Hyery Kim
Blood Res 2020; 55(S1): S5-S13
International Extranodal Lymphoma Study Group (IELSG) model in our cohort.
|@|~(^,^)~|@|Nottingham/Barcelona model in our cohort.
|@|~(^,^)~|@|Memorial Sloan-Kettering Cancer Center (MSKCC) model in our cohort.
|@|~(^,^)~|@|Newly proposed Asan Medical Center (AMC) prognostic model.